Zobrazeno 1 - 5
of 5
pro vyhledávání: ''
Autor:
Elizabeth A. Raetz, Amrana Quereshi, M. Zwaan, Nirali N. Shah, Keith J. August, Mignon L. Loh, Susan R. Rheingold, Luciano Dalla-Pozza, Richard Sposto, Jean-Pierre Bourquin, Maryalice Stetler-Stevenson, Deepa Bhojwani, Constance M. Yuan, Sarah Alexander, Paul G. Schlegel, Aurelie Cabannes, Jennifer L. McNeer, Maureen M. O'Brien, Vilmarie Rodriguez, Claudia Rossig
Publikováno v:
Leukemia, 33(4), 884-892. Nature Publishing Group
Leukemia, vol 33, iss 4
Leukemia
Leukemia, vol 33, iss 4
Leukemia
Although inotuzumab ozogamicin (InO) is recognized as an effective agent in relapsed acute lymphoblastic leukemia (ALL) in adults, data on safety and efficacy in pediatric patients are scarce. We report the use of InO in 51 children with relapsed/ref
Autor:
Ingrid M. Ariës, Edwin Cuppen, Martin A. Horstmann, C. van de Ven, Christian M. Zwaan, Elisabeth M.P. Steeghs, V de Haas, M L den Boer, Rob Pieters, Nicolle Besselink, Marco J. Koudijs, H A de Groot-Kruseman, Isabel S. Jerchel, Alex Q. Hoogkamer, Judith M. Boer, Aurélie Boeree, G Escherich
Publikováno v:
Leukemia, 32(4), 931. Nature Publishing Group
Leukemia, 32(4), 931-940. Nature Publishing Group
Leukemia
Leukemia, 32(4), 931-940. Nature Publishing Group
Leukemia
RAS pathway mutations have been linked to relapse and chemotherapy resistance in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL). However, comprehensive data on the frequency and prognostic value of subclonal mutations in well-defin
Autor:
Zita Borbényi, Suddhasatta Acharyya, Karen W.L. Yee, Je-Hwan Lee, Massimo Breccia, S. Ide, Árpád Illés, Alan Macwhannell, Carlos Graux, Miklos Egyed, Nancy Zhu, David Valcárcel, James D. Cavenagh, Reinhard Stauder, Huda Salman, Daniel J. DeAngelo, Mikkael A. Sekeres, M. Marker, Oliver G. Ottmann, G. Garcia-Manero, Lucien Gazi, Pierre Fenaux
Publikováno v:
Leukemia
Treatment with azacitidine (AZA), a demethylating agent, prolonged overall survival (OS) vs conventional care in patients with higher-risk myelodysplastic syndromes (MDS). As median survival with monotherapy is
Autor:
Eunice S. Wang, Deedra Nicolet, Andrew J. Carroll, A-K Eisfeld, Clara D. Bloomfield, Christopher J. Walker, Shelley Orwick, Jonathan E. Kolitz, Richard Stone, James S. Blachly, A de la Chapelle, John C. Byrd, Karl Kroll, Jessica Kohlschmidt, Krzysztof Mrózek, Bayard L. Powell
Publikováno v:
Leukemia
Recurrent chromosomal abnormalities and gene mutations detected at the time of diagnosis of acute myeloid leukemia (AML) are associated with particular disease features, treatment response and survival of AML patients, and are used to denote specific
Autor:
Chiara Milanesi, Chiara Cavalloni, Emanuela Sant'Antonio, Mario Cazzola, Maria C. Renna, Emanuela Boveri, Ilaria Carola Casetti, Vittorio Rosti, Elisa Roncoroni, Daniela Pietra, Elisa Rumi, Elena Fugazza, Cesare Astori, Vittorio Abbonante, C. A. Di Buduo, Francesco Moccia, Marta Bellini, Alessandra Balduini, G Barosi, Virginia Valeria Ferretti
Publikováno v:
Leukemia
A quarter of patients with essential thrombocythemia or primary myelofibrosis carry a driver mutation of CALR, the calreticulin gene. A 52-bp deletion (type 1) and a 5-bp insertion (type 2 mutation) are the most frequent variants. These indels might